ArticleInternational journal of cancer2015
Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.
Article in International journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Worldwide burden of cervical human papillomavirus (HPV) in women over 50 years with abnormal cytology: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Pooled it
- Feasibility and acceptability of HPV testing using GeneXpert for cervical cancer screening in Morocco.Scientific reports · 2026Article
- Demographic and Screening-to-Diagnosis Cascade Indicators for Risk Stratification in an Organized Cervical Cancer Screening Program: Evidence from 82,141 Women in Yunnan, China.International journal of women's health · 2026Article
- Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study.International journal of cancer · 2025Article
- Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States.Annals of internal medicine · 2025Article
- Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling.Journal of the National Cancer Institute. Monographs · 2024Article
- Age-specific 3-year risk of cervical precancer among HPV-positive women attending screening: a post hoc analysis from a retrospective cohort.Infectious agents and cancer · 2024Article
- Cervical cancer screening using DNA methylation triage in a real-world population.Nature medicine · 2024Article
- Human Papillomavirus Vaccination Status and Correlates Among Mid-Adult Women: Connecticut, USA, 2016-2019.Journal of women's health (2002) · 2024Article
- Article
- Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS.BMC women's health · 2023Article
- Evidence of latent HPV infection in older Danish women with a previous history of cervical dysplasia.Acta obstetricia et gynecologica Scandinavica · 2022Article
- Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.BMC women's health · 2021Article
- A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer.Preventive medicine · 2021Article
- Introduction of HPV testing for cervical cancer screening in Central America: The Scale-Up project.Preventive medicine · 2020Article
- Economic evaluation of HPV DNA test as primary screening method for cervical cancer: A health policy discussion in Greece.PloS one · 2019Article
- Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.Cancer causes & control : CCC · 2018Article
- Review
- Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2.International journal of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
It is unclear whether a woman's age influences her risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) upon detection of HPV. A large change in risk as women age would influence vaccination and screening policies. Among 972,029 women age 30-64 undergoing screening with Pap and HPV testing (Hybrid Capture 2, Qiagen, Germantown, MD) at Kaiser Permanente Northern California (KPNC), we calculated age-specific 5-year CIN3+ risks among women with HPV infections detected at enrollment, and among women with "newly detected" HPV infections at their second screening visit. Women (57,899, 6.0%) had an enrollment HPV infection. Among the women testing HPV negative at enrollment with a second screening visit, 16,724 (3.3%) had a newly detected HPV infection at their second visit. Both enrollment and newly detected HPV rates declined with age (p < 0.001). Women with enrollment versus newly detected HPV infection had higher 5-year CIN3+ risks: 8.5% versus 3.9%, (p < 0.0001). Risks did not increase with age but declined slightly from 30-34 years to 60-64 years: 9.4% versus 7.4% (p = 0.017) for enrollment HPV and 5.1% versus 3.5% (p = 0.014) for newly detected HPV. Among women age 30-64 in an established screening program, women with newly detected HPV infections were at lower risk than women with enrollment infections, suggesting reduced benefit vaccinating women at older ages. Although the rates of HPV infection declined dramatically with age, the subsequent CIN3+ risks associated with HPV infection declined only slightly. The CIN3+ risks among older women are sufficiently elevated to warrant continued screening through age 65.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.